Health
Excellent outcomes reported for first targeted frontline therapy for high-risk pediatric Hodgkin lymphoma – Newswise
Scientists are reporting results of the first frontline clinical trial to use targeted therapy to treat high-risk pediatric Hodgkin lymphoma.
A new kind of therapy
Brentuximab vedotin is an anti-CD30 antibody drug conjugate. The drug, which is already approved to treat adults with Hodgkin lymphoma, is targeted specifically to Hodgkin Reed Sternberg cells (cancer cells in Hodgkin lymphoma). Brentuximab vedotin delivers the medicine directly where it is needed.
“I think of brentuximab vedotin as a smart drug,” said first and corresponding author Monika Metzger, M.D., St. Jude Departments of Oncology and Global Pediatric Medicine. “Unlike conventional chemotherapy, which…
-
Noosa News10 hours agoMan dies in Brisbane crash, women and girl rushed to hospital
-
General19 hours agoProductivity summit ends day two with progress on rules changes to boost housing supply
-
Noosa News24 hours agoBIGSOUND Is Back For 2025 With Over 130 Emerging Artists
-
Noosa News22 hours agoGirl charged with attempted murder after foster carer stabbed in Ipswich